These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 21984975)

  • 1. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.
    Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA
    Cancer Discov; 2011 Jul; 1(2):158-69. PubMed ID: 21984975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
    Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
    Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kras, Pten, NF-κB, and inflammation: dangerous liaisons.
    Chiao PJ; Ling J
    Cancer Discov; 2011 Jul; 1(2):103-5. PubMed ID: 22586351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
    Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D
    Cancer Cell; 2013 Mar; 23(3):406-20. PubMed ID: 23453624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN loss accelerates KrasG12D-induced pancreatic cancer development.
    Hill R; Calvopina JH; Kim C; Wang Y; Dawson DW; Donahue TR; Dry S; Wu H
    Cancer Res; 2010 Sep; 70(18):7114-24. PubMed ID: 20807812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.
    Döppler H; Panayiotou R; Reid EM; Maimo W; Bastea L; Storz P
    Sci Rep; 2016 Sep; 6():33758. PubMed ID: 27649783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mTOR dependency in pancreatic cancer.
    Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
    Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multilevel Regulation of NF-κB Signaling by NSD2 Suppresses Kras-Driven Pancreatic Tumorigenesis.
    Feng W; Niu N; Lu P; Chen Z; Rao H; Zhang W; Ma C; Liu C; Xu Y; Gao WQ; Xue J; Li L
    Adv Sci (Weinh); 2024 Aug; 11(30):e2309387. PubMed ID: 38889281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
    Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
    Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.
    Singh K; Pruski M; Bland R; Younes M; Guha S; Thosani N; Maitra A; Cash BD; McAllister F; Logsdon CD; Chang JT; Bailey-Lundberg JM
    Lab Invest; 2021 Feb; 101(2):177-192. PubMed ID: 33009500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
    Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
    Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.
    Wang Z; Ali S; Banerjee S; Bao B; Li Y; Azmi AS; Korc M; Sarkar FH
    J Cell Physiol; 2013 Mar; 228(3):556-562. PubMed ID: 22806240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.
    Morton JP; Jamieson NB; Karim SA; Athineos D; Ridgway RA; Nixon C; McKay CJ; Carter R; Brunton VG; Frame MC; Ashworth A; Oien KA; Evans TR; Sansom OJ
    Gastroenterology; 2010 Aug; 139(2):586-97, 597.e1-6. PubMed ID: 20452353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
    Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
    Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.